These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11458014)

  • 1. Combination therapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa receptor inhibitors: SPEEDing into GUSTO V.
    Lincoff AM
    J Invasive Cardiol; 2001 May; 13 Suppl A():16A-18A. PubMed ID: 11458014
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study].
    Franzosi MG
    Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.
    Yoon HC; Miller FJ
    AJR Am J Roentgenol; 2002 Mar; 178(3):617-22. PubMed ID: 11856686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
    Sebastian M; Makkar R
    Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion.
    Kaplan AL; Goldmann B; Ohman EM
    J Emerg Med; 1999; 17(3):589-95. PubMed ID: 10338261
    [No Abstract]   [Full Text] [Related]  

  • 8. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GP IIb/IIIa blockade during peripheral artery interventions.
    Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
    Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Eur J Emerg Med; 1998 Dec; 5(4):391-402. PubMed ID: 9919443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitation of thrombolysis in acute myocardial infarction.
    Gambhir DS
    Indian Heart J; 1999; 51(5):486-8. PubMed ID: 10721636
    [No Abstract]   [Full Text] [Related]  

  • 19. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.